Researchers at Karolinska Institutet, in collaboration with colleagues at The Scripps Research Institute and Emory University ...

Lenacapavir is a twice-yearly injection to prevent HIV that could improve adherence rates compared to other PrEP medications. d3sign/Getty Images A drug used to treat some HIV infections can now be ...

Scientists have designed a DNA scaffold that carries HIV vaccine proteins into the body and sharpens the immune response against the virus. One of the biggest hurdles in developing an HIV vaccine is ...

By Deena Beasley May 5 (Reuters) - Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has ...

WASHINGTON (AP) -- The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions -- although it's unclear how ...

Gilead Sciences' twice-yearly HIV prevention injection Yeztugo has gained users since its June launch, but adoption is slowed by insurance coverage gaps, patient preference for pills, and concerns ...

SEATTLE — There is still no cure for HIV, but researchers have made huge strides to treat and prevent the infection. This month, the FDA approved a preventative drug that's being called a ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, lenacapavir, as a tool in their efforts to fight HIV infections – especially for ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Delivering a single shot of gene therapy at birth could offer children ...

Journal Editorial Report: RFK Jr's new picks play into his critics’ hands. Good news the world can use: The Food and Drug Administration last week approved Gilead Science’s twice-a-year shot that is ...